Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma
| Autor: | Chang-Min Kim, Dong Wook Koh, Woojin Lee, Ji Hoon Kim, Joong-Won Park |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Hepatitis B virus medicine.medical_specialty Carcinoma Hepatocellular Cirrhosis medicine.disease_cause Antiviral Agents Gastroenterology Internal medicine Humans Medicine Retrospective Studies Korea Hepatology business.industry Lamivudine Middle Aged Hepatitis B medicine.disease digestive system diseases Liver HBeAg Hepatocellular carcinoma Immunology Female Liver function business Viral hepatitis medicine.drug |
| Zdroj: | Liver International. 29:203-207 |
| ISSN: | 1478-3231 1478-3223 |
| DOI: | 10.1111/j.1478-3231.2008.01828.x |
| Popis: | Background/Aims: Treatment of patients with hepatocellular carcinoma (HCC) depends on the tumour extent and underlying liver function. Antiviral therapy with nucleoside/nucleotide analogues has been shown to be effective in improving the liver function of chronic hepatitis B (CHB) patients. We assessed whether lamivudine could induce biochemical and virological improvements in patients with hepatitis B virus-related HCC. Patients/Methods: Of 148 CHB patients treated with 100 mg/day lamivudine for at least 6 months, 80 had HCC (CHB/HCC group) and 68 did not (CHB group). Biochemical and virological parameters were serially monitored. Results: Compared with the CHB group, the CHB/HCC group was older, had higher male predominance, bilirubin levels and liver cirrhosis rate, and lower albumin and hepatitis B virus (HBV) DNA levels and hepatitis B e antigen (HBeAg) positivity (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|